Meeting
2022 ASCO Annual Meeting
A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
Authors
Dongmei Ji
Department of Head ＆ Neck tumors and Neuroendocrine tumors, Fudan University Shanghai Cancer Center, Shanghai, China
Dongmei Ji , Weina Shen , Muyu Kuang , Ying Liu , Huajun Li , Yu Wang , Qinghai Ji
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT04521348
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6085)
DOI
10.1200/JCO.2022.40.16_suppl.6085
Abstract #
6085
Poster Bd #
77
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
First Author: Feng Wang
Poster
2023 ASCO Annual Meeting
Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.
First Author: Lili Mao
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Yonggui Hong